Respiratory News and Research

RSS

Dual-action monoclonal antibodies from an original SARS survivor show promise against COVID-19

A recent study, currently available on the bioRxiv preprint server, indicates that a pair of dual-action monoclonal antibodies derived from an original 2003 SARS survivors could play an important role in the fight against coronavirus disease 2019 (COVID-19) due to their broadly neutralizing activity and the engagement of the immune system via effector function capabilities.

14 Mar 2021

Study maps crucial component of long-term immune response to SARS-CoV-2

Researchers in the United States have found that protective antibodies generated against the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)– the agent that causes coronavirus disease 2019 (COVID-19) – also protect against viral variants.

14 Mar 2021

Cannabis compound inhibits SARS-CoV-2 replication in human lung cells

Researchers in the United States have conducted a study showing that a cannabis plant compound inhibited infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human lung cells.

14 Mar 2021

Pragmatic recommendations for management of COVID-19 in low- and middle-income countries

A new supplement offering guidance on severe COVID-19 management in resource-limited settings is now available on the American Journal of Tropical Medicine website.

13 Mar 2021

Study finds visual correlation between severity of COVID-19 in the lungs and brain

Since the pandemic hit, researchers have been uncovering ways COVID-19 impacts other parts of the body, besides the lungs.

13 Mar 2021

Could horse-derived antibodies promote immunity against SARS-CoV-2 infection?

Researchers based in India have demonstrated that horses inoculated with an inactivated dosage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are able to produce large amounts of strong antibodies that can neutralize multiple variants

12 Mar 2021

Single-dose vaccines may provide sufficient immunization for individuals previously infected with SARS-CoV-2

A group of researchers based at the Papa Giovanni XXIII hospital in Italy have submitted evidence to suggest that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may adequately benefit from a single dose of mRNA vaccine, rather than requiring the current two-vaccine regimen.

12 Mar 2021

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

In a study published in the journal Drugs, a researcher tackled the approval of Pfizer-BioNTech’s COVID-19 vaccine, which has now been used in many countries.

12 Mar 2021

Study identifies three novel binding receptors for SARS-CoV-2

A team of scientists from the United Kingdom recently conducted a large-scale screening of several membrane-bound and soluble host cell receptors to identify novel binding partners for SARS-CoV-2. They have identified three novel receptors expressed on the human cell membrane; of which, one binds to SARS-CoV-2 spike with similar affinity as angiotensin-converting enzyme 2 (ACE2).

12 Mar 2021

Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study

As new variants of SARS-CoV-2 continue to emerge, fueling the continued spread of the COVID-19 pandemic, a new study offers encouragement.

12 Mar 2021

Impact of type I interferon (IFN) autoantibodies in critical COVID-19

A new preprint discusses the pathogenesis of this critical COVID-19 with reference to autoimmune phenomena involving the key antiviral type I interferon pathway.

12 Mar 2021

Antibodies to SARS-CoV-2 spike protein and RBD detected in saliva of mRNA-vaccine recipients

A team of researchers from the US and the Netherlands recently reported that antibodies to the spike protein and the RBD are detected in saliva samples from healthcare workers vaccinated with mRNA vaccines.

12 Mar 2021

SARS-CoV-2 is extremely sensitive to type I IFN pre-treatment, study finds

Researchers have found that SARS-CoV-2 is extremely sensitive to type I IFN pre-treatment. Therefore, strategies such as focusing on limiting the production of IFN, rather than its function, could restrict the mechanism of SARS-CoV-2 that increases its viral load with delayed or absent symptoms.

12 Mar 2021

U.S. Congress has clear opportunity to supercharge global health R&D, shows report

The U.S. Congress and Biden-Harris administration have a clear opportunity to supercharge global health research and development (R&D) in the wake of a pandemic that has revealed both the sector's chronic neglect and amazing potential.

12 Mar 2021

Tailored approach is required to fight antibiotic resistance

The global battle against antibiotic resistance can only succeed if local contexts are taken into account. "A tailored approach is needed in each country," says Heiman Wertheim of Radboud university medical center. "There is no "one-size-fits-all' solution."

12 Mar 2021

Exposure to COVID-19 can cause rare but life-threatening pediatric condition

Exposure to SARS-Co-V2, the virus that causes COVID-19, can put otherwise healthy children and adolescents at risk for Multisystem Inflammatory Syndrome in Children (MIS-C), a rare but possibly life-threatening pediatric condition that can cause severe inflammation in organs like the heart, brain, lungs, kidneys and gastrointestinal system.

12 Mar 2021

Spike protein mutations in SARS-CoV-2 variants help resist antibody neutralization

Researchers based in Beijing and Shenzhen, China, report that they have identified mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may allow variant strains to avoid neutralization by monoclonal antibodies and convalescent blood plasma.

11 Mar 2021

N501Y mutation in SARS-CoV-2 responsible for increased viral transmission

Researchers at the University of Texas, USA, have confirmed the specific mutation in the B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has allowed for it to be more transmissible than the ancestral strain. The N501Y substitution is one of 8 spike protein substitutions present in the UK variant and has also appeared convergently in the Brazil (P.1) and South Africa (B.1.351) variants.

11 Mar 2021

Structure and function of locked conformation of the SARS-CoV-2 spike protein identified

A new preprint research paper, posted to the bioRxiv* server, uncovered more information on the different structural conformations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The findings suggest the spike protein turns into a locked state to stabilize the spike protein during virus egress.

11 Mar 2021

Delaying second dose of Pfizer-BioNTech SARS-CoV-2 vaccine may be feasible in some cases

Researchers in Spain have conducted the most extensive study to date investigating the effectiveness of vaccinating healthcare workers with a single dose of the Pfizer-BioNTech vaccine to protect against coronavirus disease 2019 (COVID-19).

11 Mar 2021

Respiratory News and Research

Dual-action monoclonal antibodies from an original SARS survivor show promise against COVID-19

Study maps crucial component of long-term immune response to SARS-CoV-2

Cannabis compound inhibits SARS-CoV-2 replication in human lung cells

Pragmatic recommendations for management of COVID-19 in low- and middle-income countries

Study finds visual correlation between severity of COVID-19 in the lungs and brain

Could horse-derived antibodies promote immunity against SARS-CoV-2 infection?

Single-dose vaccines may provide sufficient immunization for individuals previously infected with SARS-CoV-2

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

Study identifies three novel binding receptors for SARS-CoV-2

Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study

Impact of type I interferon (IFN) autoantibodies in critical COVID-19

Antibodies to SARS-CoV-2 spike protein and RBD detected in saliva of mRNA-vaccine recipients

SARS-CoV-2 is extremely sensitive to type I IFN pre-treatment, study finds

U.S. Congress has clear opportunity to supercharge global health R&D, shows report

Tailored approach is required to fight antibiotic resistance

Exposure to COVID-19 can cause rare but life-threatening pediatric condition

Spike protein mutations in SARS-CoV-2 variants help resist antibody neutralization

N501Y mutation in SARS-CoV-2 responsible for increased viral transmission

Structure and function of locked conformation of the SARS-CoV-2 spike protein identified

Delaying second dose of Pfizer-BioNTech SARS-CoV-2 vaccine may be feasible in some cases

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News